BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $81 million versus the consensus estimate of $81.41 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.